GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK has acquired exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
The agreement reinforces GSK's oncology pipeline and gives Syndivia the scale to progress its promising asset. The ADC, developed by the France-based biotech firm, has shown enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted that the therapy addresses a significant unmet need, given the limited targeted treatment options for this advanced form of prostate cancer.
The deal reflects GSK's push to broaden its oncology pipeline.
Author's summary: GSK acquires rights to Syndivia's ADC asset.
More News
- We need more faith spaces that affirm the LGBTQ communities – Baptist News Global
- Two killed as gunfire erupts during funeral for airstrike victims in Chin State
- LGBTQ+ community center announces new programming
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Elon Musk’s Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Pastors and professionals
- UK businesses more likely to rely on brokers for risk management than global peers - Insurance Age
- Banging bumper fun from 2000AD!